Ozagrel HCl (78712-43-3) is a potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM)1. Does not inhibit prostacyclin (PGI2) synthase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM)1. Inhibits platelet aggregation2 in vitro and arachidonate-induced arterial contraction in vivo. Oaagrel HCl protects against arachidonate-induced sudden death in the rabbit3, and alleviates liver injury induced by acetaminophen overdose in mice4.
1) Hiraku et al. (1986), Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046); Jpn. J. Pharmacol., 41 393
2) Naito et al. (1983), Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets; Eur. J. Pharmacol., 91 41
3) Edmonds and Leffer (1984), Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death; Life Sci., 35 1763
4) Tomishima et al. (2013), Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice; BMC Gastroenterol., 30 13